A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Enrolling by invitation · NCT05979441 · Registry updated 2026-09-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | Skin and Connective Tissue Diseases, antisynthetase syndrome, connective tissue disorder, dermatomyositis, immune-mediated necrotizing myopathy, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, polymyositis, skin disorder | Enrolling by invitation | Phase 3 | 2026-09-21 | NCT05979441 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| argenx | 52 |
92 results · Page 1 of 4
Research sites
Swipe the table sideways for more columns.